Tato Pavlovsky y Elvira Onetto

En Octubre de 2014 se realizaron en la Facultad de Arte las primeras Jornadas de Dirección en Artes escénicas1. En este marco se presentó la obra Asuntos Pendientes de Tato Pavlovsky; con dirección de Elvira Onetto y las actuaciones de Susy Evans, Eduardo Misch, Paula Marrón y Eduardo Pavlovsky. A casi un año de la muerte de Tato recordamos su profundo compromiso con la cultura y el teatro, publicando estos fragmentos de la charla que él y Elvira Onetto mantuvieron con el público de las jornadas el día previo a la función. La misma fue moderada por Paula Fernández.1Estas Jornadas fueron organizadas por los docentes- investigadores: Paula Fernández, Jerónimo Ruiz, Gabriela González y Agustina Fittipaldi.  

Environmental Performance of Deconstructable Concrete Beams Made with Recycled Aggregates

The construction sector is one of the most energy-intensive and raw-material-demanding human activities and, hence, contributes a significant share of greenhouse gas emissions. As a matter of principle, making the construction sector "greener" is one of the main challenges for policy makers, private companies and the scientific community. For this reason, one of the most promising actions is based on recycling Construction and Demolition Waste (CDW) and converting them into secondary raw materials for the construction sector itself. Moreover, the reduction of the environmental impact can be further amplified through the optimization of the production, assembly and deconstruction/reuse procedures and through the maximization of the service life. In this aim, the present work aims at analyzing the environmental performance of duly sized and designed prefabricated Decontructable and Reusable Beam (DRB) incorporating with Recycled Concrete Aggregates (RCA) assembled by means of an innovative system based on a memory (R)-steel prestressing technique. The environmental performance is evaluated through Life Cycle Assessment with a cradle-to-gate approach: the analysis of 16 midpoint impact categories was conducted using the methodology proposed by EN15804. In this context, three allocation scenarios for avoided impacts due to reuse (100-0, 50:50 and 0-100) were considered, and a sensitivity analysis was performed. It was verified that due to the higher amount of post-tensioning required for the innovative shape memory alloy steel bars, the DRBs present inferior environmental performance than the Ordinary Beams (ORB). However, when analyzing the reuse scenarios, it was observed that the DRB could have considerably lower impacts, depending on the type of allocation procedure adopted in LCA modeling. This study brings as the main contribution an evaluation and some design guidelines for the development of circular concrete structures based on the principles of Design for Deconstruction (DfD) and the prefabricated process

Neurotransmisores

Se realiza una revisión bibliográfica donde se utiliza la técnica de revisión documental en el Centro de Información Médica de la Universidad Médica de Guantánamo. Se describen las características generales de las sinapsis y de las sustancias consideradas como neurotransmisores. Se describen las características particulares de los neurotransmisores de acuerdo a su división en dos grupos: neurotransmisores de pequeño tamaño molecular (acetilcolina, noradreanalina, adrenalina, dopamina, serotonina, histamina, aminoácidos excitadores e inhibidores, glicina) y péptidos neuroactivos o neuropéptidos (sustancia P y otras taquicininas, péptidos opiodes y otros polipéptidos)

Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C

Background: An estimated 170 million individuals worldwide are infected with the hepatitis C virus (HCV). Although treatment options using a combination of pegylated interferon and ribavirin (P-IFN/RBV) are available, sustained clearance of the virus is only achieved in approximately 40% of individuals infected with HCV genotype 1. Recent advances in the treatment of HCV using directly acting antiviral agents have been achieved; however, treatment can be very expensive and is associated with substantial side effects. The development of a new treatment modality is needed. One possible modality could be specific immunotherapy. Terap C is a therapeutic vaccine candidate composed of pIDKE2, a plasmid expressing HCV structural antigens, with a recombinant HCV core protein, Co.120. Objective: To assess the safety and efficacy of concomitant therapy with the candidate vaccine, Terap C, IFN α-2b and ribavirin in untreated individuals with HCV genotype 1 infection. Methods: This was a Phase II randomized, placebo-controlled, double-blind clinical trial evaluating the safety and efficacy of Terap C concomitant with IFN α-2b/RBV in 92 treatment-naïve patients with HCV genotype 1 infection. The study was conducted at the Gastroenterology Institute in Havana, Cuba. Patients were randomly assigned to 1 of 5 groups. The control group (Group 1) received IFN α-2b/RBV and placebo for 48 weeks. Groups 2 and 3 were administered Terap C 6 and 9 times, respectively, in addition to standard IFN α-2b/RBV treatment. In groups 4 and 5, Terap C was introduced 12 weeks after the initiation of IFN α-2b/RBV and administered 6 and 9 times, respectively, concomitant with IFN α-2b/RBV. Results: All patients showed some adverse events. Out of 3615 adverse events, only 18.8% were considered to be probably associated with administration of Terap C. Most events (47.4%) were considered to be improbably associated with of administration Terap C. Only 33.8% were considered possibly temporarily associated with Terap C, and can be explained by the use of conventional IFN α-2b + RBV or by HCV itself. The most common adverse events (≥65%) observed were pain at the injection site, headache, asthenia, psychiatric disturbances, fever, and gastrointestinal symptoms. Regarding sustained virological response, a 20% superiority was observed in the patients who received concomitant Terap C treatments from the beginning of the study compared with those who started after Week 12. Conclusions: Vaccination with Terap C in patients with chronic HCV infection was safe and well tolerated. Clinical trial protocol code: IG/VHI/HC/0701; Public Register Code: RPCEC00000074

Measurement of the exclusive γγ→μ+μ−\gamma \gamma \rightarrow \mu^+ \mu^- process in proton-proton collisions at s=13\sqrt{s}=13 TeV with the ATLAS detector

International audienceThe production of exclusive γγ→μ+μ− events in proton–proton collisions at a centre-of-mass energy of 13 TeV is measured with the ATLAS detector at the LHC, using data corresponding to an integrated luminosity of 3.2 fb −1 . The measurement is performed for a dimuon invariant mass of 12GeV<mμ+μ−<70GeV . The integrated cross-section is determined within a fiducial acceptance region of the ATLAS detector and differential cross-sections are measured as a function of the dimuon invariant mass. The results are compared to theoretical predictions both with and without corrections for absorptive effects